Calcium Dobesilate

A drug used to reduce hemorrhage in diabetic retinopathy.

Also Known As:

2,5-Dihydroxybenzenesulfonate; 2,5-Dihydroxybenzenesulfonic Acid; Calcium Dobesilate (1:1); Calcium Dobesilate Monoammonium Salt; Calcium Dobesilate Monopotassium Salt; Dexium; Dobica; Doxium; 2,5 Dihydroxybenzenesulfonate; 2,5 Dihydroxybenzenesulfonic Acid; Calcium, Dobesilate; Dobesilate, Calcium; Dobesilate Calcium; Benzenesulfonic acid, 2,5-dihydroxy-, calcium salt (2:1)

Networked: 174 relevant articles (15 outcomes, 42 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Chiavaroli, Carlo: 4 articles (10/2010 - 07/2004)
2.	Fatemi, Iman: 3 articles (08/2022 - 01/2021)
3.	Kaeidi, Ayat: 3 articles (08/2022 - 01/2021)
4.	Haller, Hermann: 3 articles (11/2021 - 01/2017)
5.	Ni, Zhaohui: 3 articles (01/2019 - 12/2017)
6.	Qi, Chaojun: 3 articles (01/2019 - 12/2017)
7.	Shao, Xinghua: 3 articles (01/2019 - 12/2017)
8.	Zhou, Yijun: 3 articles (01/2019 - 12/2017)
9.	Bozkurt, A K: 3 articles (08/2006 - 01/2002)
10.	Garay, Ricardo P: 3 articles (03/2005 - 07/2004)

Related Diseases

1.	Diabetic Retinopathy (Retinopathy, Diabetic) 10/01/2017 - "Calcium dobesilate (CaD) is beneficial in early stages of diabetic retinopathy (DR), but its mechanisms of action remains to be elucidated. " 01/01/2021 - "Efficacy of calcium dobesilate in treating Chinese patients with mild-to-moderate non-proliferative diabetic retinopathy (CALM-DR): protocol for a single-blind, multicentre, 24-armed cluster-randomised, controlled trial." 06/01/1978 - "Two independent, double-masked, controlled studies were made to evaluate the efficacy of calcium dobesilate for the treatment of nonproliferative diabetic retinopathy. " 01/01/1977 - "In this double-blind, randomized trial, which lasted for 2 years, the authors investigated the efficacy of calcium dobesilate on diabetic retinopathy. " 01/01/2015 - "Systematic searches of PUBMED, Springer Link and the Cochrane Clinical Trials Database were conducted using the keywords "diabetic retinopathy" and "calcium dobesilate". "
2.	Venous Insufficiency 04/01/1990 - "The aim of this double-blind placebo-controlled study was to evaluate the therapeutic efficacy of Doxium in chronic venous insufficiency (CVI). " 06/01/2011 - "To test the efficacy of calcium dobesilate (CaD) in chronic venous insufficiency (CVI). " 04/01/1990 - "Doxium 500 in chronic venous insufficiency: a double-blind placebo controlled multicentre study." 03/31/1990 - "Fourty patients with lower limb chronic venous insufficiency entered a randomised placebo controlled study with calcium dobesilate for one month. " 10/01/1988 - "Calcium dobesilate was studied in a double-blind trial in 30 normal subjects and in 30 patients with chronic venous insufficiency (CVI). "
3.	Varicose Veins (Varicose Vein) 02/01/2003 - "Calcium dobesilate, a capillotropic agent, has been found to be beneficial in the treatment of varicose veins. " 07/01/2009 - "Oxerutins and calcium dobesilate may be of benefit in reducing oedema and rutosides may help to relieve the symptoms of varicose veins in pregnancy. " 12/01/2011 - "Further studies are required to investigate whether a similar action is found in varicose veins from patients orally treated with calcium dobesilate." 08/01/2008 - "Our study highlights the significance of apoptosis in varicose disorders and suggests that calcium dobesilate, which is used in the treatment of varicose veins, could be of benefit by regulating apoptosis." 12/01/2011 - "Calcium dobesilate protected human varicose veins against oxidative stress in vitro at levels that correspond to therapeutic concentrations. "
4.	Paresthesia (Dysesthesia) 03/01/2004 - "Calcium dobesilate improved paresthesias significantly more than placebo in the severe but not in the mild group and the effect on leg volume was also significantly better in the severe group (-7.2% vs -1.6%). " 04/01/1990 - "The results show that at the end of the trial, all the examined parameters (leg oedema, pain, day and night cramps, discomfort, heavy legs, paresthesia and restless legs) were significantly more improved in the Doxium group than in the placebo group: the leg volume was diminished by 3.8% in the Doxium group compared to 1.2% in the placebo (p less than 0.005). "
5.	Pain (Aches) 10/01/2021 - "MPFF was the most effective treatment in reducing lower leg volume, CIVIQ-20 score and pain VAS scale while calcium dobesilate and Ruscus+HMC+VitC were the most effective in reducing foot volume and ankle circumference respectively.Meta" 04/01/1990 - "The results show that at the end of the trial, all the examined parameters (leg oedema, pain, day and night cramps, discomfort, heavy legs, paresthesia and restless legs) were significantly more improved in the Doxium group than in the placebo group: the leg volume was diminished by 3.8% in the Doxium group compared to 1.2% in the placebo (p less than 0.005). "

Related Drugs and Biologics

1.	Alprostadil (Muse)
2.	cyclo(Arg-Pro) (CI 4)
3.	Calcium Dobesilate
4.	CLS 2210
5.	Antioxidants
6.	Biomarkers (Surrogate Marker)
7.	Therapeutic Uses
8.	Retinaldehyde (Retinal)
9.	Calcium
10.	Glutathione (Reduced Glutathione)

Related Therapies and Procedures

1.	Therapeutics
2.	Light Coagulation
3.	Lasers (Laser)
4.	Percutaneous Coronary Intervention
5.	Lenses